secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2022-01-06T23:59:59+00:00
Accession:  0000914475-22-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Biosciences reports preliminary Q4 2021 INGREZZA sales ~$301M, FY ~$1.1B
--------------------------------------------------------------------------------

- Q4 INGREZZA net sales ~$301M ($296M inventory-adjusted), up 25% YoY; prescriptions up 32% YoY.
- Full-year 2021 INGREZZA net sales ~$1.1B.
- Full-year 2022 INGREZZA sales guidance to be provided on Feb 11, 2022 earnings call.
- Pipeline: sNDA for valbenazine in Huntington chorea in 2H 2022; Phase 2 data for NBI-827104 mid-2022.
- Company now has 13 mid-to-late-stage clinical programs with data readouts over the next two years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447522000004/0000914475-22-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447522000004/nbix-20220106.htm
  HTML page:      https://secwatch.observer/filing/0000914475-22-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer